NEW YORK (GenomeWeb News) – Imaging company Definiens and the cancer treatment technology company Clarient have agreed to co-develop tools for evaluating cancer biomarkers, Clarient said today.
 
Under the terms of the five-year agreement, the companies will develop a series of image analysis tools that Clarient will use in its internal research programs and will also offer through its PathSite customer web portal.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.